Genomics Revolutionizing Hospital Systems
Bleeding edge Industrialization of Genomics: A Novel Business Opportunity to a Hospital System – to Calibrate by Whole Genome DNA Analytics, the Efficacy of Chemotherapy Drugs: Wider Global implications.
Guest Article – By Ram Ramanujam, Founder-President &CEO, Propinquity Therapeutics, A RNA CGT Company, Bangalore, India.
The very essence of this techno commerce al article is to pinpoint and address the so far unmet needs in various Cancer treatments by Whole Genome Testing and Genome Guided Therapy and diagnostics. The global and Indian opportunity is expressed as part of the avenues for this line of treatment and cure. Hundreds of chemotherapy drugs are used – but we are in the early beginnings of the era when they are rated for efficacy by the successful mitigation of massive genomic changes as cancer is a genome regulation disease. With cancer, the Cell and Genome Therapy by programmable biology is possible now.
Ram Ramanujam spearheaded a conference in the 2012/2017 march at Hyderabad in India, where ideas were truly nurtured, and a scalable global business model was secured for the globe.
Recognition by the government agencies of the priority of the idea might have been delayed not only because of
the now-recognized cross-disciplinary nature of genome informatics but also since it represents a massive paradigm shift from “dark matter” and “Central Dogma” and Fractal cancer. Thus, the idea and its utility were initially perceived by many as a double heresy. Eric Lander et al. putting the Hilbert- fractal of the genome on the cover of Science on Oct. 9, 2009, changed all that.NIH Head Francis Collins urged “the scientific community to re-think long-held fundamentals.” Now in the form of another batch of 30+ papers of the US government- led ENCODE arrived again on September 6th, 2012, the result that “dark matter” is anything but junk. As the realm of the Old School has finally come to an end after more than half a Century after Francis Crick’s Central Dogma and forty years after Susumu Ohno’s Junk DNA, the New School of “Industrialized Genomics based on fractal and genome analytics of genome informatics” can now hyper escalate and scalable.“The more comprehensive Picture Proposed by Ram Ramanujam is promoting for the globe lends a unique opportunity for India to catch up to China where Beijing Genome Institute in Shenzhen pursues genomic syndromes in a strategic relationship with Merck Beijing, and BGI, with sequencing, analytics, and clinical trials are followed abroad from the USA to optimize economic feasibility by outsourcing. Scarcity of matching analytics of sequencing technology that outdid Moore’s Law – not counting the incomparably more enormous losses of valuation by Illumina.
As pharma experts in US Silicon Valley quoted, “With time, a Microsoft or Google type IT will acquire – or build– an IT-led pharma.” Theoretical physicist Academician Sergey Petoukhov (Moscow, Russia, pointed out that “the history of physics amply documents this point that breakthroughs lead to innovations of significant practicality – a special opportunity for India we are closely familiar with”.
“Cancer appears to be a genome regulation derailment. For the success but even for the economic planning of any Moon Shot, the mathematically defined trajectory of the target could be useful” – possibly referring to hundreds of millions gravely affected by genome regulation syndromes amidst a global economic hardship of taxpayers.
The broader picture by Ram Ramanujam lends itself as instrumental progressions to India’s ambition to become a global player in the Genome Informatics area. An IT-led Pharma, a Sequencing facility, a Clinical trial facility, a Hospital system, and a Genome Informatics enterprise are essential ingredients to put together the big picture. The business model is a robust, global, scalable, and repeatable scheme that is designed to sustain accelerating growth in the areas of Cross disciplines of Biology and Informatics. The essence of the project is that cancer presents such a destructive disease for humankind that today’s treatments of cancer fall short of predicted outcomes. The treatment is based now more- or less on “trial and error” for hundreds of different chemotherapy drug treatments available (just from a single manufacturer, Roche).
What makes the matter even worse for treatment outcomes is that the endpoints predicted now have a weak correlation with the treatment patterns. Without rigorous genome checking, doctors are largely left to guess the next course of action after chemo. THE GENOME-GUIDED CALIBRATION OF DRUGS removes these lacunae. It leaves the patient at ease as he knows that the patient is genome tested for the treatment of chemos. Once the patient is normal, before chemo and after chemo are genome tested, then essentially, the course of action for therapy can be decided on more solid footing than intelligent guesses.
The model can be oversimplified to a “washer and dryer” set-up. In the hospital setting, samples will be collected and sequenced, and the genome will be analyzed for repeats, such as Copy Number Variations that are already known to be an altered factor in the genomes of cancer patients. Such CNV-s (copy number variations) may be stationary or can get better (or worse) during chemotherapy in comparison with normal DNA, revealed by sequencing and analysis of the DNA of patients before chemo, during treatment, and after chemo. Now that Genome analytics is based on Fractal Genomics, intellectual property is secured for fractal defect mining as CNV-s represents the largest fractal defects. The patented algorithmic approach secures analysis of the genomes of cancer patients for fractal defects, and CNV analysis in the framework of full fractal shifts tells us which chemo is best suited, as judged by genome testing and analysis.
This model also requires clinical trials to be conducted for genome testing of the patients. For each step, include Sequencing of the DNA, Genome analytics. Big Pharma sponsors the Genome-Based Calibration of the Efficacy of their chemo drug repertory.
Genomics Revolutionizing Hospital Systems
Here the broader picture by Ram Ramanujam takes shape in addressing the unmet need of the present day cancer treatment and addresses Genome Guided Therapy as an individualized solution for the presently “one size fits all” approach to the treatment of cancer patients. CNV implications are proven by dozens of top-rated articles by independent experimental clinicians for many cancer types, and thus CNV analysis plays a central role in genome-based testing.
Ram Ramanujam arrived at the global business model after over a dozen years by now. They concluded that an outsourcing model to India is an excellent opportunity for Genome Analytics and Genome-based testing for cancer patients and treatment options. Ram Ramanujam is a trained Biologist with 32 years of experience domain expert in Genomics and modern Biology. Ram Ramanujam is a collaborator, business savvy, experienced scientist who is spearheading the business aspects of the Big Picture and serves as the chief Business negotiator with global counterparts.
With the current thrust in sub-100 dollar genomes and the least expensive exome and Whole genome sequencing, this big picture is aptly fitting the Indian middle-income population. It will be well served to consider its applicability to the masses. While India is stressed as a market potential for this big picture offered here, the rest of the world can also benefit from the inventions and applications in the cure of Cancer. Will the ten-dollar genome in a decade augment the arrival of Genome Guided Testing and Therapeutics? Time will tell.
Keyword: Genomics Revolutionizing Hospital Systems
